Skip to Content
Upcoming Webinar

CAR T-Cell Therapy: Health Care Resource Utilization + Costs in DLBCL Patients

Date: January 27, 2026 | 2:00 PM

Date: Tuesday, January 27 | 2 p.m. EST
Presenter: Madelyn Floysand, PharmD | NCODA

CAR-T therapy is changing quickly, and as more programs explore outpatient delivery, it raises an important question: what does the real-world resource and cost picture actually look like?

In this CE-accredited session, Madelyn Floysand, PharmD, breaks down findings from the 2025 Journal of Managed Care & Specialty Pharmacy article by Patel et al., walking through how DLBCL patients receiving CAR-T differ in hospital stays, ICU use, outpatient visits, and 30-day post-infusion costs depending on whether care is delivered inpatient or outpatient. You’ll leave with practical insights you can use to support patient selection, workflow planning, and interdisciplinary care coordination as CAR-T programs continue to grow.

Learning Objectives

  • Describe the study design, data sources, and methodology used in the 2025 Journal of Managed Care and Specialty Pharmacy article by Patel et al. as it relates to health care resource utilization and costs inpatients with Diffuse Large B-Cell Lymphoma (DLBCL) receiving Chimeric Antigen Receptor T-cell (CAR-T) therapy.
    Compare the differences in hospitalization patterns, intensive care unit (ICU) utilization, and outpatient resource use between inpatient and outpatient CAR-T administration in the 2025 Journal of Managed Care and Specialty Pharmacy article by Patel et al.
    Identify key cost drivers contributing to total health care expenditures during the 30-day post-infusion period for patients receiving CAR T-cell therapy and compare cost patterns across inpatient and outpatient sites of care in the 2025 Journal of Managed Care and Specialty Pharmacy article by Patel et al.
    Discuss how real-world evidence from the 2025 Journal of Managed Care and Specialty Pharmacy article by Patel et al. can inform patient selection, operational planning, and interdisciplinary care models for CAR-T delivery.

 

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.